Brief: BioCryst Pharmaceuticals Q3 EPS USD -0.19
02/11/2023 11:01
Nov 02 (Reuters) - BioCryst Pharmaceuticals Q3 product sales USD 86.742 million vs. IBES estimate USD 86 million. * Q3 operating income USD -11.921 million * Q3 net income USD -36.149 million * Q3 operating expenses USD 98.663 million * Q3 pretax profit USD -35.819 million
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026